Malignant Brain Tumor Clinical Trial
— NODDI-TRACTOfficial title:
Evaluation of the Contribution of NODDI Protocol Tractography in Brain Tumor Surgery
Verified date | December 2022 |
Source | GCS Ramsay Santé pour l'Enseignement et la Recherche |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this study is to evaluate to what extent the capacity of the NODDI model can allow, in case of Malignant brain tumor patients with vasogenic edema, the elaboration of a reliable cerebral functional mapping in accordance with the data of direct electrical stimulation (DES) which is today the reference tool. the patient's participation in this study implies an additional visit during which an MRI examination without injection of contrast medium will be performed, lasting approximately 40 minutes (including installation and de-installation).
Status | Not yet recruiting |
Enrollment | 12 |
Est. completion date | February 1, 2024 |
Est. primary completion date | February 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient 18 years of age or older, - Patient who has read and signed the consent form for participation in the study - Patient requiring surgery for a malignant brain tumor with vasogenic edema - Patient with an estimated life expectancy of more than 3 months. Exclusion Criteria: - Patient under legal protection, guardianship or trusteeship - Patient not affiliated to the French social security system - Contraindication to MRI (patient with a pacemaker or cardiac defibrillator, implanted equipment activated by an electrical, magnetic or mechanical system, patient with hemostatic clips on intracerebral aneurysms or with orthopedic implants, claustrophobic patient) - Psychiatric history - Refusal to be informed of an abnormality detected during the MRI - Pregnant or breastfeeding woman |
Country | Name | City | State |
---|---|---|---|
France | Clinique de l'Union | Saint-Jean |
Lead Sponsor | Collaborator |
---|---|
GCS Ramsay Santé pour l'Enseignement et la Recherche |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Response to electrical stimulation | Response to electrical stimulation, which determines the presence or absence of an essential bundle, is the primary end point.
The ability of the NODDI-tract method to reconstruct essential bundles in vasogenic edema will be assessed by estimating the correspondence between the response to intraoperative direct electrical stimulation (DES) and the presence of an MRI reconstructed bundle. Based on the response to electrical stimulation, the NODDI-tract data will be classified into one of four groups: True positive = response to stimulation and presence of an MRI beam True negative = no response to stimulation and no beam on MRI False positive = no response to stimulation and presence of a beam on MRI False-negative = response to stimulation and absence of beam in MRI. The distance between the reconstructed beam and the stimulation point (whether or not the stimulation was effective) will also be measured. |
Hour 24 | |
Secondary | Number of reconstructed fibers | Reconstructions obtained using the NODDI protocol or tractography will be compared on the total number of fibers reconstructed by both methods.
The comparison will be made on the total number of reconstructed fibers and on the number of reconstructed fibers crossing the edema. |
Hour 24 | |
Secondary | Average distance to a reference atlas | The comparison is based on the evaluation of the average distance between the skeleton of the NODDI-tract reconstructed beams and that of the JHU tractography atlas [20]. The distance will be calculated by projecting the reconstructed skeleton onto the atlas skeleton, and as a function of the length traveled on the parameterized curve representing the skeleton. This function will be averaged over the entire length of the skeleton. An average distance of less than 1cm will be considered as a match criterion. | Hour 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04109209 -
Psychological Intervention For Brain Tumor Caregivers
|
N/A | |
Completed |
NCT02798406 -
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
|
Phase 2 | |
Completed |
NCT04351035 -
National Wide Cross-sectional Study in Paediatric Central Nervous System Tumours in China -- the CNOG-MC001 Registry
|
||
Completed |
NCT02502708 -
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
|
Phase 1 | |
Recruiting |
NCT05976490 -
NeuroPathways Intervention for Brain Tumor Patients
|
N/A | |
Terminated |
NCT02128373 -
A Computer-Based Intervention for Distance Caregivers of Parents With Advanced Cancer
|
N/A | |
Terminated |
NCT02885324 -
Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children
|
Phase 2 | |
Not yet recruiting |
NCT06099743 -
ASCENT Intervention for Brain Tumor Patients
|
N/A | |
Terminated |
NCT02880111 -
Rates DMBT1 ( Glycoprotein) in Sputum of CF Patients With Pseudomonas Aeruginosa
|
||
Completed |
NCT02052648 -
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06098248 -
cCeLL - Ex Vivo (Confocal Fluorescence Endomicroscopy) for Intraoperative Brain Tumor Diagnosis
|
N/A | |
Completed |
NCT00418327 -
Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma
|
Phase 1 | |
Recruiting |
NCT05293197 -
Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients
|
Phase 1 | |
Recruiting |
NCT06092125 -
Clinical Applicantion of Multi-Tracer PET/MR Imaging in Neurological Disorders/Disease
|
||
Suspended |
NCT05169944 -
Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors
|
Phase 1 |